218 related articles for article (PubMed ID: 23900343)
21. Validated predictive QSAR modeling of N-aryl-oxazolidinone-5-carboxamides for anti-HIV protease activity.
Halder AK; Jha T
Bioorg Med Chem Lett; 2010 Oct; 20(20):6082-7. PubMed ID: 20832304
[TBL] [Abstract][Full Text] [Related]
22. The efficacy of conceptual DFT descriptors and docking scores on the QSAR models of HIV protease inhibitors.
Srivastava HK; Choudhury C; Sastry GN
Med Chem; 2012 Sep; 8(5):811-25. PubMed ID: 22741804
[TBL] [Abstract][Full Text] [Related]
23. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
Arodola OA; Soliman ME
Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
[TBL] [Abstract][Full Text] [Related]
24. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
Frecer V; Burello E; Miertus S
Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
[TBL] [Abstract][Full Text] [Related]
25. Fullerene derivative as anti-HIV protease inhibitor: molecular modeling and QSAR approaches.
Ibrahim M; Saleh NA; Elshemey WM; Elsayed AA
Mini Rev Med Chem; 2012 Jun; 12(6):447-51. PubMed ID: 22587761
[TBL] [Abstract][Full Text] [Related]
26. QSAR prediction of HIV-1 protease inhibitory activities using docking derived molecular descriptors.
Fatemi MH; Heidari A; Gharaghani S
J Theor Biol; 2015 Mar; 369():13-22. PubMed ID: 25600056
[TBL] [Abstract][Full Text] [Related]
27. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach.
Jenwitheesuk E; Samudrala R
Antivir Ther; 2005; 10(1):157-66. PubMed ID: 15751773
[TBL] [Abstract][Full Text] [Related]
28. A priori molecular descriptors in QSAR: a case of HIV-1 protease inhibitors. II. Molecular graphics and modeling.
Kiralj R; Ferreira MM
J Mol Graph Model; 2003 Jun; 21(6):499-515. PubMed ID: 12676237
[TBL] [Abstract][Full Text] [Related]
29. Deformation density components analysis of fullerene-based anti-HIV drugs.
Fakhraee S; Souri M
J Mol Model; 2014 Nov; 20(11):2486. PubMed ID: 25388278
[TBL] [Abstract][Full Text] [Related]
30. Fullerene derivatives as dual inhibitors of HIV-1 reverse transcriptase and protease.
Yasuno T; Ohe T; Kataoka H; Hashimoto K; Ishikawa Y; Furukawa K; Tateishi Y; Kobayashi T; Takahashi K; Nakamura S; Mashino T
Bioorg Med Chem Lett; 2021 Jan; 31():127675. PubMed ID: 33161121
[TBL] [Abstract][Full Text] [Related]
31. Revealing interaction mode between HIV-1 protease and mannitol analog inhibitor.
Yan GW; Chen Y; Li Y; Chen HF
Chem Biol Drug Des; 2012 Jun; 79(6):916-25. PubMed ID: 22296911
[TBL] [Abstract][Full Text] [Related]
32. Molecular dynamics study of the connection between flap closing and binding of fullerene-based inhibitors of the HIV-1 protease.
Zhu Z; Schuster DI; Tuckerman ME
Biochemistry; 2003 Feb; 42(5):1326-33. PubMed ID: 12564936
[TBL] [Abstract][Full Text] [Related]
33. Fullerene-based inhibitors of HIV-1 protease.
Strom TA; Durdagi S; Ersoz SS; Salmas RE; Supuran CT; Barron AR
J Pept Sci; 2015 Dec; 21(12):862-70. PubMed ID: 26767741
[TBL] [Abstract][Full Text] [Related]
34. Optimization and computational evaluation of a series of potential active site inhibitors of the V82F/I84V drug-resistant mutant of HIV-1 protease: an application of the relaxed complex method of structure-based drug design.
Perryman AL; Lin JH; Andrew McCammon J
Chem Biol Drug Des; 2006 May; 67(5):336-45. PubMed ID: 16784458
[TBL] [Abstract][Full Text] [Related]
35. Optimizing the binding of fullerene inhibitors of the HIV-1 protease through predicted increases in hydrophobic desolvation.
Friedman SH; Ganapathi PS; Rubin Y; Kenyon GL
J Med Chem; 1998 Jun; 41(13):2424-9. PubMed ID: 9632374
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, screening and computational investigation of pentacycloundecane-peptoids as potent CSA-HIV PR inhibitors.
Makatini MM; Petzold K; Arvidsson PI; Honarparvar B; Govender T; Maguire GE; Parboosing R; Sayed Y; Soliman ME; Kruger HG
Eur J Med Chem; 2012 Nov; 57():459-67. PubMed ID: 22867528
[TBL] [Abstract][Full Text] [Related]
37. 3D-QSAR studies on chromone derivatives as HIV-1 protease inhibitors: application of molecular field analysis.
Nunthanavanit P; Anthony NG; Johnston BF; Mackay SP; Ungwitayatorn J
Arch Pharm (Weinheim); 2008 Jun; 341(6):357-64. PubMed ID: 18442018
[TBL] [Abstract][Full Text] [Related]
38. Design of peptidomimetic inhibitors of aspartic protease of HIV-1 containing -Phe Psi Pro- core and displaying favourable ADME-related properties.
Frecer V; Berti F; Benedetti F; Miertus S
J Mol Graph Model; 2008 Oct; 27(3):376-87. PubMed ID: 18678515
[TBL] [Abstract][Full Text] [Related]
39. Computational studies of darunavir into HIV-1 protease and DMPC bilayer: necessary conditions for effective binding and the role of the flaps.
Leonis G; Czyżnikowska Ż; Megariotis G; Reis H; Papadopoulos MG
J Chem Inf Model; 2012 Jun; 52(6):1542-58. PubMed ID: 22587384
[TBL] [Abstract][Full Text] [Related]
40. QSAR studies on HIV-1 protease inhibitors using non-linearly transformed descriptors.
Saranya N; Selvaraj S
Curr Comput Aided Drug Des; 2012 Mar; 8(1):10-49. PubMed ID: 21999608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
